US trial set for noninvasive fertility monitor:
This article was originally published in Clinica
Pheromone Sciences is to begin a multicentre, 140-patient clinical trial of its noninvasive PSC Fertility Monitor in the US. Researchers will compare the device, which predicts ovulation by measuring ion changes on the skin's surface, with current techniques for detecting fertility and ovulation. The Toronto, Ontario-based company already has marketing clearance for the device in Canada. It plans to submit a US marketing application for the test by the end of the year.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.